AUROPHARMA2022-10-012022-12-31 AUROPHARMA2022-10-012022-12-31 AUROPHARMA2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2022-10-012022-12-31in-bse-fin:OneOperatingExpenses02Member AUROPHARMA2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member AUROPHARMA2022-10-012022-12-31in-bse-fin:FourOperatingExpenses02Member AUROPHARMA2022-12-31 AUROPHARMA2022-10-012022-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2022-10-012022-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2022-10-012022-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2022-10-012022-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2022-10-012022-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AUROPHARMA2022-10-012022-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524804 AUROPHARMA NOTLISTED Aurobindo Pharma Limited Equity 2022-04-01 2023-03-31 2023-02-09 2023-01-31 INR Millions Third quarter 14:30:00 18:20:00 2023-02-09 2023-02-09 Not applicable Single segment Pharmaceutical Products 2022-10-01 2022-12-31 Unaudited Consolidated 64071300000.00 926500000.00 64997800000.00 26214900000.00 5379500000.00 -2518800000.00 9217200000.00 449600000.00 3214000000.00 16234400000.00 58190800000.00 6807000000.00 0.00 6807000000.00 1360700000.00 530300000.00 1891000000.00 0.00 4916000000.00 0.00 0.00 0.00 -5900000.00 4910100000.00 4765800000.00 9675900000.00 4912600000.00 -2500000.00 9678400000.00 -2500000.00 585900000.00 1 8.38 8.38 0.00 0.00 8.38 8.38 1. The above consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on Consolidated financial statements and Ind AS 28 on Investments in Associates and Joint ventures notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended. 3. The above consolidated financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 9, 2023. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended December 31, 2022. An unmodified report has been issued by them thereon. 4. Exceptional items represent the following items which have been credited/(debited) to consolidated statement of profit and loss. Particulars Quarter and nine months ended December 31, 2021 Year ended March 31, 2022 Gain on sale of tangible assets * 1,156.7 1,160.3 Impairment of intangible assets and goodwill ** (808.8) (1,490.0) Impairment of capital work in progress** - (950.0) Total 347.9 (1,279.7) * Gain on sale and lease back of Group's real estate property situated in Dayton, New Jersey, USA. ** Due to uncertain regulatory development and change in business plan impacting the goodwill, intangible assets, capital work in progress relating to certain products, the Group recorded an impairment charge of Rs. 2,440.1. 5. The Group operates in only one reportable segment viz., 'Pharmaceutical Products'. 6. During the quarter, Auro Steriles LLC was dissolved w.e.f September 30, 2022. 7. During the previous quarter, a) Auro Cure Private Limited, India renamed itself as Eugia Steriles Private Limited, w.e.f. July 26, 2022. b) Wytells Pharma Private Limited, India renamed itself as Eugia SEZ Private Limited, w.e.f. September 2, 2022. c) Auro Medics Pharma LLC, USA renamed itself as Eugia US LLC, w.e.f. August 8, 2022. d) TheraNyM Biologics Private Limited, India was incorporated w.e.f. September 22, 2022. e) PT Aurogen Pharma Indonesia was incorporated w.e.f. July 1, 2022. Continued notes in segment......... Single segment 2022-04-01 2022-12-31 Unaudited Consolidated 183824200000.00 1783300000.00 185607500000.00 69819400000.00 14616800000.00 -813300000.00 26703500000.00 848800000.00 8990100000.00 46559700000.00 166725000000.00 18882500000.00 0.00 18882500000.00 4910900000.00 -303900000.00 4607000000.00 0.00 14275500000.00 0.00 0.00 0.00 -58100000.00 14217400000.00 7225000000.00 21442400000.00 14212300000.00 5100000.00 21437300000.00 5100000.00 585900000.00 1 24.26 24.26 0.00 0.00 24.26 24.26 Foreign Exchange loss (net) 0.00 Other Expenses 16234400000.00 Foreign Exchange loss (net) 622300000.00 Other Expenses 45937400000.00 continued.... 8. a) The Board of Directors of the Aurobindo Pharma limited (Holding Company) at its meeting held on March 28, 2022 approved the acquisition of business including certain assets of Veritaz Healthcare Limited (Veritaz). Consequently the Holding Company entered into a definitive agreement with Veritaz for the said acquisition for total consideration of Rs. 1,710 and obtained control effective April 1, 2022 over such business and assets. b) The Board of Directors of the Holding Company at its meeting held on June 17, 2022 approved investment in GLS Pharma Limited (GLS) through subscription of 204,819 equity shares for an aggregate consideration of Rs. 93.5 (constituting 17% of the equity share capital of GLS) and acquisition of 409,339 equity shares from the selling shareholders for an aggregate consideration of Rs. 187 (constituting of 34% of equity share capital of GLS). During the quarter ended June 30, 2022, the Holding Company subscribed to 204,819 equity shares of GLS consequent to execution of share subscription and purchase agreement. During the previous quarter on satisfaction of the closing conditions, the Company acquired the additional 409,339 equity share. Consequent to the above acquisitions, the results of the current quarter/period are strictly not comparable to the previous quarters/periods. 9. During the quarter ended March 31, 2022, the Holding Company elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Holding Company has recognised provision for income tax for the year ended March 31, 2022 and re-measured its deferred tax assets /liabilities based on the rate prescribed in the said Section. The impact of this change has been recognised in the statement of profit and loss during the year ended March 31, 2022. 10. The Board of Directors at their meeting held on February 9, 2023 declared an interim dividend of Rs. 3 per equity share (Face value Re.1. 11. The consolidated financial results of the Group for the quarter and nine months ended December 31, 2021 were reviewed by the predecessor auditors (M/s BSR & Associates LLP, Chartered Accountants), who have expressed an unmodified review conclusion. The consolidated financial results of the Group for the year ended March 31, 2022 were audited by the predecessor auditors (M/s BSR & Associates LLP, Chartered Accountants), who have expressed an unmodified audit opinion. Re-measurment of defined employee benefit liablity 22400000.00 Equity investment through other comprehensive income-net change in fair value 54600000.00 Re-measurment of defined employee benefit liablity 71900000.00 Equity investment through other comprehensive income-net change in fair value -88100000.00 77000000.00 -16200000.00 5000000.00 18600000.00 Exchange differences on translating the financial statements of foreign operations 4693800000.00 Exchange differences on translating the financial statements of foreign operations 7259800000.00 4693800000.00 7259800000.00 0.00 0.00